X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
波士顿，2024年12月3日（环球新闻社）-- x4制药（纳斯达克股票代码：XFOR）是一家致力于改善罕见免疫系统疾病患者生活的公司，今天宣布，自2024年12月2日起，该公司根据x4制药公司2019年引诱性股权激励计划（"2019引诱性计划"）向新员工发放引诱性奖励。2019引诱性计划专门用于向以前不是x4员工的个人授予股权奖励。引诱性奖励包括购买x4普通股396,824股的期权。这些股票奖励是作为对新员工与x4签订就业协议的诱因而授予的，符合纳斯达克上市规则5635（c）（4）的规定，并已获得x4董事会薪酬委员会的批准。
The options have a ten-year term and an exercise price of $0.371 per share, which is equal to the closing price of X4's common stock on December 2, 2024. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.
这些期权有十年期限，行权价格为每股0.371美元，与2024年12月2日x4普通股的收盘价相同。每个期权将在四年内分批授予，其中25%的股份将在12个月后获得，其余股份将在接下来的36个月内每月获得，前提是员工在这些获权日期继续与x4合作。这些期权受2019年引诱性计划的条款和条件以及涵盖授予的奖励协议的条款和条件约束。
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .
关于x4制药
X4制药正在为罕见免疫系统疾病患者提供进展，并开发和推广创新治疗方案，以满足他们的重大未满足需求。利用我们在CXCR4和免疫系统生物学方面的专业知识，我们已成功开发了mavorixafor，并在其第一个适应症中获得了美国批准 - XOLREMDI（mavorixafor）胶囊。我们还在评估mavorixafor在其他潜在适应症中的使用。X4制药的总部位于美国马萨诸塞州波士顿，研究中心位于奥地利维也纳。欲了解更多信息，请访问我们的网站。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司联系人：
Jose Juves
企业和患者事务负责人
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投资者联系人：
Daniel Ferry
LifeSci Advisors董事总经理
daniel@lifesciadvisors.com
(617) 430-7576
